Abbott and Seradyn Announce U.S. Clearance for Hemoglobin A(1C) (HbA(1C)) Test For Diabetes
March 05 2004 - 9:44AM
PR Newswire (US)
Abbott and Seradyn Announce U.S. Clearance for Hemoglobin A(1C)
(HbA(1C)) Test For Diabetes - By Monitoring Glucose Levels,
Patients Can Help Reduce Their Risk Of Developing Long-Term
Diabetic Complications (Blindness, Amputation and Kidney Damage) -
ABBOTT PARK, Ill., March 5 /PRNewswire-FirstCall/ -- Abbott
Laboratories announced today that its development partner, Seradyn,
has received clearance from the U.S. Food and Drug Administration
(FDA) for a hemoglobin A(1C) (HbA(1C)) assay for use on Abbott's
ARCHITECT(R) c8000(TM), ARCHITECT(R) ci8200 and Aeroset(R)
immunochemistry systems. Tracking hemoglobin A(1C) levels through
lab testing provides doctors with the data they need to monitor
their patients' diabetes and prescribe the appropriate treatment.
Abbott's Multigent(TM) HbA(1C) assay provides precise and accurate
test results and gives labs an efficient and cost-effective test
that can be integrated into their current systems. Abbott will
exclusively distribute the Multigent(TM) HbA(1C) test. "Our
Multigent(TM) HbA(1C) test uses standardization, defined by the
National Glycohemoglobin Standardization Program, or NGSP, and will
provide consistent and precise reporting of results," said Jim
Koziarz, Ph.D., vice president, research and development,
diagnostics, Abbott Laboratories. "The treatment of diabetes is
based on the control of blood sugar levels. For the day-to-day
control of blood sugars, home blood glucose monitoring gives
patients the information they need daily. However, it is also
important to assess the overall control of blood sugars by
monitoring glycohemoglobin A(1C). This is a routine lab test that
all doctors are running on their patients with diabetes every three
to four months and changes in treatment, diet and exercise programs
are based on these results," said Arturo R. Rolla, M.D., associate
clinical professor of medicine, Harvard Medical School. Diabetes
mellitus is a chronic disease affecting an estimated 177 million
people worldwide and this number continues to grow. Early diagnosis
and monitoring of the disease is key to managing and preventing
serious complications and premature death. About Seradyn Since
1984, Seradyn has been an industry leader in the development of
products and technologies for research and clinical markets
worldwide. Seradyn is a leading diagnostic reagent developer in the
areas of therapeutic drug monitoring (TDM) and human serology.
Seradyn is a subsidiary of Apogent Technologies Inc. (NYSE:AOT) a
leading manufacturer of clinical diagnostic and life science
research products. For more information, visit Seradyn's Web site
at http://www.seradyn.com/ . About Abbott Laboratories Abbott
Laboratories is a global, broad-based health care company devoted
to the discovery, development, manufacture and marketing of
pharmaceuticals, nutritionals and medical products, including
devices and diagnostics. The company employs more than 70,000
people and markets its products in more than 130 countries. Abbott
's news releases and other information are available on the
company's Web site at http://www.abbott.com/ . DATASOURCE: Abbott
Laboratories CONTACT: Media, Amy Woodworth, +1-847-935-4755, or
Financial Community, Christy Wistar, +1-847-938-4475, both of
AbbottLaboratories Web site: http://www.abbott.com/
http://www.seradyn.com/ Company News On-Call:
http://www.prnewswire.com/comp/110328.html
Copyright
Apogent (NYSE:AOT)
Historical Stock Chart
From May 2024 to Jun 2024
Apogent (NYSE:AOT)
Historical Stock Chart
From Jun 2023 to Jun 2024